Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease ; volume:15 ; number:1 ; day:16 ; month:10 ; year:2017 ; pages:1-13 ; date:12.2017
BMC medicine ; 15, Heft 1 (16.10.2017), 1-13, 12.2017
- Urheber
-
Bjerrum, Jacob Tveiten
- Beteiligte Personen und Organisationen
-
Steenholdt, Casper
Ainsworth, Mark
Nielsen, Ole Haagen
Reed, Michelle AC
Atkins, Karen
Günther, Ulrich Leonhard
Hao, Fuhua
Wang, Yulan
SpringerLink (Online service)
- DOI
-
10.1186/s12916-017-0949-7
- URN
-
urn:nbn:de:1111-2017120713597
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:19 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bjerrum, Jacob Tveiten
- Steenholdt, Casper
- Ainsworth, Mark
- Nielsen, Ole Haagen
- Reed, Michelle AC
- Atkins, Karen
- Günther, Ulrich Leonhard
- Hao, Fuhua
- Wang, Yulan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Loss of Calreticulin Uncovers a Critical Role for Calcium in Regulating Cellular Lipid Homeostasis
Rewiring phospholipid biosynthesis reveals resilience to membrane perturbations and uncovers regulators of lipid homeostasis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Loss of Calreticulin Uncovers a Critical Role for Calcium in Regulating Cellular Lipid Homeostasis
Rewiring phospholipid biosynthesis reveals resilience to membrane perturbations and uncovers regulators of lipid homeostasis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Loss of Calreticulin Uncovers a Critical Role for Calcium in Regulating Cellular Lipid Homeostasis
Rewiring phospholipid biosynthesis reveals resilience to membrane perturbations and uncovers regulators of lipid homeostasis
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study